SIRION Biotech bringing latest viral vector insights to ELRIG Drug Discovery ’15
Press Release | SIRION Biotech GmbH
AUGUST 25, 2015
Martinsried, Germany: – Viral technology specialist SIRION Biotech will once again be an active participant at the upcoming ELRIG – Drug Discovery 2015 (ELRIG-DD15) conference (September 2nd-3rd).
The company will be sharing its latest insights and advances in viral vector technologies and cell modeling at the conference, a leading forum for EU decision makers in sciences and the biotech industry working in drug discovery and therapy development.
SIRION will be reviewing its progress on accelerating cell-based projects using innovative vector designs. It will share particular insights on its technological advances for gene therapy such as its growing AAV (adeno-associated virus) platform and how to achieve world-leading T-cell transduction rates.
Face to face meetings
The SIRION team will include Dr. Kathrin Schmitt, Director of Business Development & Sales, and Dr. Franziska Ruf, newly appointed Key Account Manager for UK and German speaking areas.
SIRION is inviting all ELRIG-DD15 delegates to contact the company and set up face-to-face meetings with Dr. Schmitt or Dr. Ruf during the conference in Telford, UK.
Dr. Schmidt explained: “SIRION has been a participant of the ELRIG conferences for several years. This is a superb forum for us to share our knowledge with fellow scientists and company representatives working in cell based research areas of drug discovery, regenerative medicine and gene therapy.”
As a world leader in customizing viral vectors, SIRION can provide unique services and technologies to build first class cell models. This expedites and elevates research to achieve better data faster.”
Dr. Franziska Ruf added: “In my former position as stem cell researcher I had to do all my virus constructions myself. It took so much of my time. If I had enjoyed access to a custom vector supplier back then, it would have improved the timing of my work considerably.”
About SIRION Biotech
SIRION BIOTECH is Europe’s leading commercial supplier of viral vectors used for genetic research, gene target validation, gene therapy development and vaccination studies.
In business since 2007, SIRION’s mission is to change the paradigm for viral vector supplies. It has the ability to customize and produce all common viral vector types (adenovirus, lentivirus and AAV) within a matter of weeks.
The company also offers a full range of virus related products and services, ranging from transduction enhancing agents to fully customized cell models including the transformative RNAiONE™ knockdown validation platform.
With this comprehensive viral vector portfolio, SIRION offers a suitable option for almost any preclinical in-vitro and in-vivo application.
About ELRIG DD15
The European Laboratory Research & Innovation Group (ELRIG) is a UK-based not-for-profit organisation serving the needs of the drug discovery and life science communities across Europe. The group is a leading organizer of scientific meetings and conferences that bring together academic and biopharma industry experts and thought leaders to exchange ideas and information.
ELRIG’s flagship event, “Drug Discovery” now attracts more than 1,300 delegates, making it the biggest conference of its kind in Europe.
Drug Discovery ’15 is a two-day event, opening September 2 at the Telford International Conference Centre in Shropshire, UK.
The conference will feature streams on Metabolic & Cardiovascular Drug Discovery, Chemistry Innovation in Lead Discovery, Target Identification & Validation, as well as Innovation in Assay Development & Screening and will also feature an exhibition.
More information at: http://elrig.org/portfolio/drug-discovery-2015/
Dr. Franziska Ruf; SIRION Biotech Key account Manager, UK and German-speaking (DACH) markets
Tel: +49 700 961 9928
Click on SIRION Biotech gears up for ELRIG Drug Discovery ’15 for other information.
Click on SIRION to contact the company directly.